213 related articles for article (PubMed ID: 25638556)
1. Outcomes and endpoints in cancer trials: bridging the divide.
Wilson MK; Collyar D; Chingos DT; Friedlander M; Ho TW; Karakasis K; Kaye S; Parmar MK; Sydes MR; Tannock IF; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e43-52. PubMed ID: 25638556
[TBL] [Abstract][Full Text] [Related]
2. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
Wilson MK; Karakasis K; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
[TBL] [Abstract][Full Text] [Related]
3. Perils of the Pathologic Complete Response.
Rose BS; Winer EP; Mamon HJ
J Clin Oncol; 2016 Nov; 34(33):3959-3962. PubMed ID: 27551115
[No Abstract] [Full Text] [Related]
4. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
5. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
Herzog TJ; Armstrong DK; Brady MF; Coleman RL; Einstein MH; Monk BJ; Mannel RS; Thigpen JT; Umpierre SA; Villella JA; Alvarez RD
Gynecol Oncol; 2014 Jan; 132(1):8-17. PubMed ID: 24239753
[TBL] [Abstract][Full Text] [Related]
7. Refining endpoints in brain tumor clinical trials.
Meyers CA; Rock EP; Fine HA
J Neurooncol; 2012 Jun; 108(2):227-30. PubMed ID: 22451194
[TBL] [Abstract][Full Text] [Related]
8. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
9. Outcome measures in multimodal rectal cancer trials.
Fokas E; Glynne-Jones R; Appelt A; Beets-Tan R; Beets G; Haustermans K; Marijnen C; Minsky BD; Ludmir E; Quirke P; Sebag-Montefiore D; Garcia-Aguilar J; Gambacorta MA; Valentini V; Buyse M; Rödel C
Lancet Oncol; 2020 May; 21(5):e252-e264. PubMed ID: 32359501
[TBL] [Abstract][Full Text] [Related]
10. Patients' understanding of oncology clinical endpoints: A literature review.
Boudewyns V; Southwell BG; DeFrank JT; Ferriola-Bruckenstein K; Halpern MT; O'Donoghue AC; Sullivan HW
Patient Educ Couns; 2020 Sep; 103(9):1724-1735. PubMed ID: 32273145
[TBL] [Abstract][Full Text] [Related]
11. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
12. Endpoints in oncology clinical trials.
Kilickap S; Demirci U; Karadurmus N; Dogan M; Akinci B; Sendur MAN
J BUON; 2018 Dec; 23(7):1-6. PubMed ID: 30722104
[TBL] [Abstract][Full Text] [Related]
13. Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
A'Hern RP
J Clin Oncol; 2016 Oct; 34(28):3474-6. PubMed ID: 27507871
[No Abstract] [Full Text] [Related]
14. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
15. Assessment of endpoints for clinical trials for localized prostate cancer.
Schellhammer P; Cockett A; Boccon-Gibod L; Gospodarowicz M; Krongrad A; Thompson IM; Scardino P; Soloway M; Adolfsson J
Urology; 1997 Apr; 49(4A Suppl):27-38. PubMed ID: 9111612
[TBL] [Abstract][Full Text] [Related]
16. Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?
Johnson P; Greiner W; Al-Dakkak I; Wagner S
Biomed Res Int; 2015; 2015():865101. PubMed ID: 26161418
[TBL] [Abstract][Full Text] [Related]
17. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.
Aprile G; Fontanella C; Bonotto M; Rihawi K; Lutrino SE; Ferrari L; Casagrande M; Ongaro E; Berretta M; Avallone A; Rosati G; Giuliani F; Fasola G
Oncotarget; 2015 Oct; 6(30):28716-30. PubMed ID: 26308250
[TBL] [Abstract][Full Text] [Related]
18. When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
Oxnard GR; Morris MJ; Hodi FS; Baker LH; Kris MG; Venook AP; Schwartz LH
J Natl Cancer Inst; 2012 Oct; 104(20):1534-41. PubMed ID: 22927506
[TBL] [Abstract][Full Text] [Related]
19. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
20. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
